Direct reprogramming of pancreatic nonendocrine cells into insulin-producing β-cells represents a promising approach for the treatment of insulin-dependent diabetes. However, its clinical application is limited by the potential for insertional mutagenesis associated with the viral vectors currently used for cell reprogramming. With the aim of developing a nonintegrative reprogramming strategy for derivation of insulin-producing cells, here, we evaluated a new approach utilizing synthetic messenger RNAs encoding reprogramming transcription factors. Administration of synthetic mRNAs encoding three key transcription regulators of β-cell differentiation-Pdx1, Neurogenin3, and MafA-efficiently reprogrammed the pancreatic exocrine cells into insulin-producing cells. In addition to the insulin genes expression, the synthetic mRNAs also induced the expressions of genes important for proper pancreatic β-cell function, including Sur1, Kir6.2, Pcsk1, and Pcsk2. Pretreating cells with the chromatin-modifying agent 5-Aza-2'-deoxycytidine further enhanced reprogramming efficiency, increasing the proportion of insulin-producing cells from 3.5 ± 0.9 to 14.3 ± 1.9% (n = 4). Moreover, 5-Aza-2'-deoxycytidine pretreatment enabled the reprogrammed cells to respond to glucose challenge with increased insulin secretion. In conclusion, our results support that the reprogramming of pancreatic exocrine cells into insulin-producing cells, induced by synthetic mRNAs encoding pancreatic transcription factors, represents a promising approach for cell-based diabetes therapy.

Department of Diabetes Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

See more in PubMed

Shapiro, AM, Ricordi, C, Hering, BJ, Auchincloss, H, Lindblad, R, Robertson, RP et al. (2006). International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355: 1318–1330. PubMed

Kroon, E, Martinson, LA, Kadoya, K, Bang, AG, Kelly, OG, Eliazer, S et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 26: 443–452. PubMed

Pagliuca, FW, Millman, JR, Gürtler, M, Segel, M, Van Dervort, A, Ryu, JH et al. (2014). Generation of functional human pancreatic β cells in vitro. Cell 159: 428–439. PubMed PMC

Ben-David, U, Arad, G, Weissbein, U, Mandefro, B, Maimon, A, Golan-Lev, T et al. (2014). Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. Nat Commun 5: 4825. PubMed

Peterson, SE and Loring, JF (2014). Genomic instability in pluripotent stem cells: implications for clinical applications. J Biol Chem 289: 4578–4584. PubMed PMC

Vierbuchen, T, Ostermeier, A, Pang, ZP, Kokubu, Y, Südhof, TC and Wernig, M (2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463: 1035–1041. PubMed PMC

Song, K, Nam, YJ, Luo, X, Qi, X, Tan, W, Huang, GN et al. (2012). Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485: 599–604. PubMed PMC

Sekiya, S and Suzuki, A (2011). Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475: 390–393. PubMed

Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872. PubMed

Takahashi, K and Yamanaka, S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676. PubMed

Akinci, E, Banga, A, Greder, LV, Dutton, JR and Slack, JM (2012). Reprogramming of pancreatic exocrine cells towards a beta (β) cell character using Pdx1, Ngn3 and MafA. Biochem J 442: 539–550. PubMed PMC

Lima, MJ, Docherty, HM, Chen, Y and Docherty, K (2012). Efficient differentiation of AR42J cells towards insulin-producing cells using pancreatic transcription factors in combination with growth factors. Mol Cell Endocrinol 358: 69–80. PubMed

Banga, A, Akinci, E, Greder, LV, Dutton, JR and Slack, JM (2012). In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. Proc Natl Acad Sci USA 109: 15336–15341. PubMed PMC

Zhou, Q, Brown, J, Kanarek, A, Rajagopal, J and Melton, DA (2008). In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455: 627–632. PubMed PMC

Banga, A, Greder, LV, Dutton, JR and Slack, JM (2014). Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist. Gene Ther 21: 19–27. PubMed PMC

Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467: 318–322. PubMed PMC

Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415–419. PubMed

Stephen, SL, Montini, E, Sivanandam, VG, Al-Dhalimy, M, Kestler, HA, Finegold, M et al. (2010). Chromosomal integration of adenoviral vector DNA in vivo. J Virol 84: 9987–9994. PubMed PMC

Stephen, SL, Sivanandam, VG and Kochanek, S (2008). Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med 10: 1176–1189. PubMed

Yu, J, Hu, K, Smuga-Otto, K, Tian, S, Stewart, R, Slukvin, II et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science 324: 797–801. PubMed PMC

Zhou, H, Wu, S, Joo, JY, Zhu, S, Han, DW, Lin, T et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4: 381–384. PubMed PMC

Seki, T, Yuasa, S, Oda, M, Egashira, T, Yae, K, Kusumoto, D et al. (2010). Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7: 11–14. PubMed

Miyoshi, N, Ishii, H, Nagano, H, Haraguchi, N, Dewi, DL, Kano, Y et al. (2011). Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8: 633–638. PubMed

Warren, L, Manos, PD, Ahfeldt, T, Loh, YH, Li, H, Lau, F et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618–630. PubMed PMC

Schlaeger, TM, Daheron, L, Brickler, TR, Entwisle, S, Chan, K, Cianci, A et al. (2015). A comparison of non-integrating reprogramming methods. Nat Biotechnol 33: 58–63. PubMed PMC

Longnecker, DS, Lilja, HS, French, J, Kuhlmann, E and Noll, W (1979). Transplantation of azaserine-induced carcinomas of pancreas in rats. Cancer Lett 7: 197–202. PubMed

Rosewicz, S, Riecken, EO and Wiedenmann, B (1992). The amphicrine pancreatic cell line AR42J: a model system for combined studies on exocrine and endocrine secretion. Clin Investig 70: 205–209. PubMed

Zhou, J, Wang, X, Pineyro, MA and Egan, JM (1999). Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48: 2358–2366. PubMed

Bruin, JE, Erener, S, Vela, J, Hu, X, Johnson, JD, Kurata, HT et al. (2014). Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Res 12: 194–208. PubMed

Karikó, K and Weissman, D (2007). Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 10: 523–532. PubMed

Barber, GN (2001). Host defense, viruses and apoptosis. Cell Death Differ 8: 113–126. PubMed

Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154–157. PubMed

Nallagatla, SR, Toroney, R and Bevilacqua, PC (2008). A brilliant disguise for self RNA: 5'-end and internal modifications of primary transcripts suppress elements of innate immunity. RNA Biol 5: 140–144. PubMed PMC

Lima, MJ, Muir, KR, Docherty, HM, Drummond, R, McGowan, NW, Forbes, S et al. (2013). Suppression of epithelial-to-mesenchymal transitioning enhances ex vivo reprogramming of human exocrine pancreatic tissue toward functional insulin-producing β-like cells. Diabetes 62: 2821–2833. PubMed PMC

Blum, B, Hrvatin, SS, Schuetz, C, Bonal, C, Rezania, A and Melton, DA (2012). Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. Nat Biotechnol 30: 261–264. PubMed PMC

Li, W, Nakanishi, M, Zumsteg, A, Shear, M, Wright, C, Melton, DA et al. (2014). In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypes. Elife 3: e01846. PubMed PMC

Schaffer, AE, Taylor, BL, Benthuysen, JR, Liu, J, Thorel, F, Yuan, W et al. (2013). Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. PLoS Genet 9: e1003274. PubMed PMC

Sander, M, Neubüser, A, Kalamaras, J, Ee, HC, Martin, GR and German, MS (1997). Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev 11: 1662–1673. PubMed

Schwitzgebel, VM, Scheel, DW, Conners, JR, Kalamaras, J, Lee, JE, Anderson, DJ et al. (2000). Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. Development 127: 3533–3542. PubMed

Taylor, BL, Liu, FF and Sander, M (2013). Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells. Cell Rep 4: 1262–1275. PubMed PMC

Gosmain, Y, Katz, LS, Masson, MH, Cheyssac, C, Poisson, C and Philippe, J (2012). Pax6 is crucial for β-cell function, insulin biosynthesis, and glucose-induced insulin secretion. Mol Endocrinol 26: 696–709. PubMed PMC

Ediger, BN, Du, A, Liu, J, Hunter, CS, Walp, ER, Schug, J et al. (2014). Islet-1 Is essential for pancreatic β-cell function. Diabetes 63: 4206–4217. PubMed PMC

Schaffer, AE, Freude, KK, Nelson, SB and Sander, M (2010). Nkx6 transcription factors and Ptf1a function as antagonistic lineage determinants in multipotent pancreatic progenitors. Dev Cell 18: 1022–1029. PubMed PMC

Arda, HE, Benitez, CM and Kim, SK (2013). Gene regulatory networks governing pancreas development. Dev Cell 25: 5–13. PubMed PMC

White, P, May, CL, Lamounier, RN, Brestelli, JE and Kaestner, KH (2008). Defining pancreatic endocrine precursors and their descendants. Diabetes 57: 654–668. PubMed

Lee, J, Sugiyama, T, Liu, Y, Wang, J, Gu, X, Lei, J et al. (2013). Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells. Elife 2: e00940. PubMed PMC

Chen, T and Dent, SY (2014). Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet 15: 93–106. PubMed PMC

van Arensbergen, J, García-Hurtado, J, Moran, I, Maestro, MA, Xu, X, Van de Casteele, M et al. (2010). Derepression of Polycomb targets during pancreatic organogenesis allows insulin-producing beta-cells to adopt a neural gene activity program. Genome Res 20: 722–732. PubMed PMC

Xie, R, Everett, LJ, Lim, HW, Patel, NA, Schug, J, Kroon, E et al. (2013). Dynamic chromatin remodeling mediated by polycomb proteins orchestrates pancreatic differentiation of human embryonic stem cells. Cell Stem Cell 12: 224–237. PubMed PMC

Sosa-Pineda, B, Chowdhury, K, Torres, M, Oliver, G and Gruss, P (1997). The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature 386: 399–402. PubMed

Collombat, P, Mansouri, A, Hecksher-Sorensen, J, Serup, P, Krull, J, Gradwohl, G et al. (2003). Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes Dev 17: 2591–2603. PubMed PMC

Wang, J, Elghazi, L, Parker, SE, Kizilocak, H, Asano, M, Sussel, L et al. (2004). The concerted activities of Pax4 and Nkx2.2 are essential to initiate pancreatic beta-cell differentiation. Dev Biol 266: 178–189. PubMed

Thess, A, Grund, S, Mui, BL, Hope, MJ, Baumhof, P, Fotin-Mleczek, M et al. (2015). Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther 23: 1456–1464. PubMed PMC

Triana-Alonso, FJ, Dabrowski, M, Wadzack, J and Nierhaus, KH (1995). Self-coded 3'-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J Biol Chem 270: 6298–6307. PubMed

Karikó, K, Muramatsu, H, Ludwig, J and Weissman, D (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39: e142. PubMed PMC

Synthetic mRNA is a more reliable tool for the delivery of DNA-targeting proteins into the cell nucleus than fusion with a protein transduction domain